Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 224 entries
Sorted by: Best Match Show Resources per page
Time to Consider Fractional Flow Reserve-Guided Percutaneous Coronary Intervention for Distal Left Main Bifurcation.

JACC. Cardiovascular interventions

Boukhris M, Mansour S.
PMID: 31439342
JACC Cardiovasc Interv. 2019 Aug 26;12(16):1625. doi: 10.1016/j.jcin.2019.05.041.

No abstract available.

Cite
Boukhris M, Mansour S. Time to Consider Fractional Flow Reserve-Guided Percutaneous Coronary Intervention for Distal Left Main Bifurcation. JACC Cardiovasc Interv. 2019;12(16):1625doi: 10.1016/j.jcin.2019.05.041.
Boukhris, M., & Mansour, S. (2019). Time to Consider Fractional Flow Reserve-Guided Percutaneous Coronary Intervention for Distal Left Main Bifurcation. JACC. Cardiovascular interventions, 12(16), 1625. https://doi.org/10.1016/j.jcin.2019.05.041
Boukhris, Marouane, and Mansour, Samer. "Time to Consider Fractional Flow Reserve-Guided Percutaneous Coronary Intervention for Distal Left Main Bifurcation." JACC. Cardiovascular interventions vol. 12,16 (2019): 1625. doi: https://doi.org/10.1016/j.jcin.2019.05.041
Boukhris M, Mansour S. Time to Consider Fractional Flow Reserve-Guided Percutaneous Coronary Intervention for Distal Left Main Bifurcation. JACC Cardiovasc Interv. 2019 Aug 26;12(16):1625. doi: 10.1016/j.jcin.2019.05.041. PMID: 31439342.
Copy Download .nbib Format: NLM
The empowerment of all modalities against cancer.

Singapore medical journal

Han S, Toh HC.
PMID: 30498843
Singapore Med J. 2018 Nov;59(11):560-561. doi: 10.11622/smedj.2018133.

No abstract available.

Cite
Han S, Toh HC. The empowerment of all modalities against cancer. Singapore Med J. 2018;59(11):560-561doi: 10.11622/smedj.2018133.
Han, S., & Toh, H. C. (2018). The empowerment of all modalities against cancer. Singapore medical journal, 59(11), 560-561. https://doi.org/10.11622/smedj.2018133
Han, Shuting, and Toh, Han Chong. "The empowerment of all modalities against cancer." Singapore medical journal vol. 59,11 (2018): 560-561. doi: https://doi.org/10.11622/smedj.2018133
Han S, Toh HC. The empowerment of all modalities against cancer. Singapore Med J. 2018 Nov;59(11):560-561. doi: 10.11622/smedj.2018133. PMID: 30498843; PMCID: PMC6250756.
Copy Download .nbib Format: NLM
Clinical outcomes of bioresorbable vascular scaffolds implanted with routine versus selective optical coherence tomography guidance: results from a single-centre experience.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology

Floré V, Brown AJ, Giblett JP, Liou K, Cranley J, Hoole SP, West NEJ.
PMID: 30375333
EuroIntervention. 2019 Apr 20;14(17):1776-1783. doi: 10.4244/EIJ-D-18-00262.

AIMS: We aimed to investigate the effects of an initial learning period with mandatory optical coherence tomography (OCT) guidance for the implantation of everolimus-eluting bioresorbable vascular scaffolds (BVS).METHODS AND RESULTS: We analysed procedural and clinical outcomes of all BVS...

Cite
Floré V, Brown AJ, Giblett JP, et al. Clinical outcomes of bioresorbable vascular scaffolds implanted with routine versus selective optical coherence tomography guidance: results from a single-centre experience. EuroIntervention. 2019;14(17):1776-1783doi: 10.4244/EIJ-D-18-00262.
Floré, V., Brown, A. J., Giblett, J. P., Liou, K., Cranley, J., Hoole, S. P., & West, N. E. J. (2019). Clinical outcomes of bioresorbable vascular scaffolds implanted with routine versus selective optical coherence tomography guidance: results from a single-centre experience. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 14(17), 1776-1783. https://doi.org/10.4244/EIJ-D-18-00262
Floré, Vincent, et al. "Clinical outcomes of bioresorbable vascular scaffolds implanted with routine versus selective optical coherence tomography guidance: results from a single-centre experience." EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology vol. 14,17 (2019): 1776-1783. doi: https://doi.org/10.4244/EIJ-D-18-00262
Floré V, Brown AJ, Giblett JP, Liou K, Cranley J, Hoole SP, West NEJ. Clinical outcomes of bioresorbable vascular scaffolds implanted with routine versus selective optical coherence tomography guidance: results from a single-centre experience. EuroIntervention. 2019 Apr 20;14(17):1776-1783. doi: 10.4244/EIJ-D-18-00262. PMID: 30375333.
Copy Download .nbib Format: NLM
Mendelian randomization and estimation of treatment efficacy for chronic diseases.

American journal of epidemiology

Schooling CM, Freeman G, Cowling BJ.
PMID: 23585329
Am J Epidemiol. 2013 May 15;177(10):1128-33. doi: 10.1093/aje/kws344. Epub 2013 Apr 12.

Prevention and treatment of common noncommunicable chronic diseases have been revolutionized by the development of therapies. Recently, several randomized controlled trials (RCTs) designed to assess the efficacy of new therapies targeted at well-established risk factors for noncommunicable chronic diseases...

Cite
Schooling CM, Freeman G, Cowling BJ. Mendelian randomization and estimation of treatment efficacy for chronic diseases. Am J Epidemiol. 2013;177(10):1128-33doi: 10.1093/aje/kws344.
Schooling, C. M., Freeman, G., & Cowling, B. J. (2013). Mendelian randomization and estimation of treatment efficacy for chronic diseases. American journal of epidemiology, 177(10), 1128-33. https://doi.org/10.1093/aje/kws344
Schooling, C M, et al. "Mendelian randomization and estimation of treatment efficacy for chronic diseases." American journal of epidemiology vol. 177,10 (2013): 1128-33. doi: https://doi.org/10.1093/aje/kws344
Schooling CM, Freeman G, Cowling BJ. Mendelian randomization and estimation of treatment efficacy for chronic diseases. Am J Epidemiol. 2013 May 15;177(10):1128-33. doi: 10.1093/aje/kws344. Epub 2013 Apr 12. PMID: 23585329.
Copy Download .nbib Format: NLM
Rethinking the dose-response relationship between usage and outcome in an online intervention for depression: randomized controlled trial.

Journal of medical Internet research

Donkin L, Hickie IB, Christensen H, Naismith SL, Neal B, Cockayne NL, Glozier N.
PMID: 24135213
J Med Internet Res. 2013 Oct 17;15(10):e231. doi: 10.2196/jmir.2771.

BACKGROUND: There is now substantial evidence that Web-based interventions can be effective at changing behavior and successfully treating psychological disorders. However, interest in the impact of usage on intervention outcomes has only been developed recently. To date, persistence with...

Cite
Donkin L, Hickie IB, Christensen H, et al. Rethinking the dose-response relationship between usage and outcome in an online intervention for depression: randomized controlled trial. J Med Internet Res. 2013;15(10):e231doi: 10.2196/jmir.2771.
Donkin, L., Hickie, I. B., Christensen, H., Naismith, S. L., Neal, B., Cockayne, N. L., & Glozier, N. (2013). Rethinking the dose-response relationship between usage and outcome in an online intervention for depression: randomized controlled trial. Journal of medical Internet research, 15(10), e231. https://doi.org/10.2196/jmir.2771
Donkin, Liesje, et al. "Rethinking the dose-response relationship between usage and outcome in an online intervention for depression: randomized controlled trial." Journal of medical Internet research vol. 15,10 (2013): e231. doi: https://doi.org/10.2196/jmir.2771
Donkin L, Hickie IB, Christensen H, Naismith SL, Neal B, Cockayne NL, Glozier N. Rethinking the dose-response relationship between usage and outcome in an online intervention for depression: randomized controlled trial. J Med Internet Res. 2013 Oct 17;15(10):e231. doi: 10.2196/jmir.2771. PMID: 24135213; PMCID: PMC3806549.
Copy Download .nbib Format: NLM
Meaningful change in oncology quality-of-life instruments: a systematic literature review.

Expert review of pharmacoeconomics & outcomes research

Bedard G, Zeng L, Lam H, Cella D, Zhang L, Lauzon N, Chow E.
PMID: 22971034
Expert Rev Pharmacoecon Outcomes Res. 2012 Aug;12(4):475-83. doi: 10.1586/erp.12.34.

Quality of life (QoL) is increasingly being recognized as an important end point in oncology clinical trials. The purpose of this study was to review the literature on what constitutes a meaningful change in oncology QoL instruments. A literature...

Cite
Bedard G, Zeng L, Lam H, et al. Meaningful change in oncology quality-of-life instruments: a systematic literature review. Expert Rev Pharmacoecon Outcomes Res. 2012;12(4):475-83doi: 10.1586/erp.12.34.
Bedard, G., Zeng, L., Lam, H., Cella, D., Zhang, L., Lauzon, N., & Chow, E. (2012). Meaningful change in oncology quality-of-life instruments: a systematic literature review. Expert review of pharmacoeconomics & outcomes research, 12(4), 475-83. https://doi.org/10.1586/erp.12.34
Bedard, Gillian, et al. "Meaningful change in oncology quality-of-life instruments: a systematic literature review." Expert review of pharmacoeconomics & outcomes research vol. 12,4 (2012): 475-83. doi: https://doi.org/10.1586/erp.12.34
Bedard G, Zeng L, Lam H, Cella D, Zhang L, Lauzon N, Chow E. Meaningful change in oncology quality-of-life instruments: a systematic literature review. Expert Rev Pharmacoecon Outcomes Res. 2012 Aug;12(4):475-83. doi: 10.1586/erp.12.34. PMID: 22971034.
Copy Download .nbib Format: NLM
Bariatric Surgery Worldwide: Baseline Demographic Description and One-Year Outcomes from the Fourth IFSO Global Registry Report 2018.

Obesity surgery

Welbourn R, Hollyman M, Kinsman R, Dixon J, Liem R, Ottosson J, Ramos A, Våge V, Al-Sabah S, Brown W, Cohen R, Walton P, Himpens J.
PMID: 30421326
Obes Surg. 2019 Mar;29(3):782-795. doi: 10.1007/s11695-018-3593-1. Epub 2018 Nov 12.

BACKGROUND: Since 2014, the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) has produced an annual report of all bariatric surgery submitted to the Global Registry. We describe baseline demographics of international practice from the 4th...

Cite
Welbourn R, Hollyman M, Kinsman R, et al. Bariatric Surgery Worldwide: Baseline Demographic Description and One-Year Outcomes from the Fourth IFSO Global Registry Report 2018. Obes Surg. 2018;29(3):782-795doi: 10.1007/s11695-018-3593-1.
Welbourn, R., Hollyman, M., Kinsman, R., Dixon, J., Liem, R., Ottosson, J., Ramos, A., Våge, V., Al-Sabah, S., Brown, W., Cohen, R., Walton, P., & Himpens, J. (2019). Bariatric Surgery Worldwide: Baseline Demographic Description and One-Year Outcomes from the Fourth IFSO Global Registry Report 2018. Obesity surgery, 29(3), 782-795. https://doi.org/10.1007/s11695-018-3593-1
Welbourn, Richard, et al. "Bariatric Surgery Worldwide: Baseline Demographic Description and One-Year Outcomes from the Fourth IFSO Global Registry Report 2018." Obesity surgery vol. 29,3 (2019): 782-795. doi: https://doi.org/10.1007/s11695-018-3593-1
Welbourn R, Hollyman M, Kinsman R, Dixon J, Liem R, Ottosson J, Ramos A, Våge V, Al-Sabah S, Brown W, Cohen R, Walton P, Himpens J. Bariatric Surgery Worldwide: Baseline Demographic Description and One-Year Outcomes from the Fourth IFSO Global Registry Report 2018. Obes Surg. 2019 Mar;29(3):782-795. doi: 10.1007/s11695-018-3593-1. Epub 2018 Nov 12. PMID: 30421326.
Copy Download .nbib Format: NLM
Efficacy and safety of colorectal endoscopic submucosal dissection in patients with sarcopenia.

Surgical endoscopy

Goto S, Arimoto J, Higurashi T, Takahashi K, Ohkubo N, Kawamura N, Tamura T, Tomonari H, Iwasaki A, Taniguchi L, Chiba H, Atsukawa K, Saigusa Y, Nakajima A.
PMID: 32989535
Surg Endosc. 2021 Oct;35(10):5489-5496. doi: 10.1007/s00464-020-08041-1. Epub 2020 Sep 28.

BACKGROUND: Endoscopic submucosal dissection (ESD) for early-stage colorectal cancer (CRC) has become a common and useful treatment. Although sarcopenia has been identified as an independent risk factor for complications after surgery for CRC, whether sarcopenia is also an independent...

Cite
Goto S, Arimoto J, Higurashi T, et al. Efficacy and safety of colorectal endoscopic submucosal dissection in patients with sarcopenia. Surg Endosc. 2020;35(10):5489-5496doi: 10.1007/s00464-020-08041-1.
Goto, S., Arimoto, J., Higurashi, T., Takahashi, K., Ohkubo, N., Kawamura, N., Tamura, T., Tomonari, H., Iwasaki, A., Taniguchi, L., Chiba, H., Atsukawa, K., Saigusa, Y., & Nakajima, A. (2021). Efficacy and safety of colorectal endoscopic submucosal dissection in patients with sarcopenia. Surgical endoscopy, 35(10), 5489-5496. https://doi.org/10.1007/s00464-020-08041-1
Goto, Shungo, et al. "Efficacy and safety of colorectal endoscopic submucosal dissection in patients with sarcopenia." Surgical endoscopy vol. 35,10 (2021): 5489-5496. doi: https://doi.org/10.1007/s00464-020-08041-1
Goto S, Arimoto J, Higurashi T, Takahashi K, Ohkubo N, Kawamura N, Tamura T, Tomonari H, Iwasaki A, Taniguchi L, Chiba H, Atsukawa K, Saigusa Y, Nakajima A. Efficacy and safety of colorectal endoscopic submucosal dissection in patients with sarcopenia. Surg Endosc. 2021 Oct;35(10):5489-5496. doi: 10.1007/s00464-020-08041-1. Epub 2020 Sep 28. PMID: 32989535.
Copy Download .nbib Format: NLM
Website Terms of Use May Limit Research about Online Physician Reviews.

Annals of vascular surgery

Egleston BL, McNeill JF, Howell KJ.
PMID: 32890651
Ann Vasc Surg. 2021 Jan;70:e7. doi: 10.1016/j.avsg.2020.08.102. Epub 2020 Sep 03.

No abstract available.

Cite
Egleston BL, McNeill JF, Howell KJ. Website Terms of Use May Limit Research about Online Physician Reviews. Ann Vasc Surg. 2020;70:e7doi: 10.1016/j.avsg.2020.08.102.
Egleston, B. L., McNeill, J. F., & Howell, K. J. (2021). Website Terms of Use May Limit Research about Online Physician Reviews. Annals of vascular surgery, 70e7. https://doi.org/10.1016/j.avsg.2020.08.102
Egleston, Brian L, et al. "Website Terms of Use May Limit Research about Online Physician Reviews." Annals of vascular surgery vol. 70 (2021): e7. doi: https://doi.org/10.1016/j.avsg.2020.08.102
Egleston BL, McNeill JF, Howell KJ. Website Terms of Use May Limit Research about Online Physician Reviews. Ann Vasc Surg. 2021 Jan;70:e7. doi: 10.1016/j.avsg.2020.08.102. Epub 2020 Sep 03. PMID: 32890651; PMCID: PMC7744426.
Copy Download .nbib Format: NLM
Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma: prognostic value of combined performance status and modified Glasgow prognostic score.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery

Ueki Y, Takahashi T, Ota H, Shodo R, Yamazaki K, Horii A.
PMID: 32239313
Eur Arch Otorhinolaryngol. 2020 Aug;277(8):2341-2347. doi: 10.1007/s00405-020-05945-5. Epub 2020 Apr 01.

PURPOSE: The importance of nivolumab for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) is rapidly increasing. However, prognostic factors have not been determined for predicting treatment outcome. We aimed to investigate the prognostic factors in...

Cite
Ueki Y, Takahashi T, Ota H, et al. Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma: prognostic value of combined performance status and modified Glasgow prognostic score. Eur Arch Otorhinolaryngol. 2020;277(8):2341-2347doi: 10.1007/s00405-020-05945-5.
Ueki, Y., Takahashi, T., Ota, H., Shodo, R., Yamazaki, K., & Horii, A. (2020). Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma: prognostic value of combined performance status and modified Glasgow prognostic score. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 277(8), 2341-2347. https://doi.org/10.1007/s00405-020-05945-5
Ueki, Yushi, et al. "Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma: prognostic value of combined performance status and modified Glasgow prognostic score." European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery vol. 277,8 (2020): 2341-2347. doi: https://doi.org/10.1007/s00405-020-05945-5
Ueki Y, Takahashi T, Ota H, Shodo R, Yamazaki K, Horii A. Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma: prognostic value of combined performance status and modified Glasgow prognostic score. Eur Arch Otorhinolaryngol. 2020 Aug;277(8):2341-2347. doi: 10.1007/s00405-020-05945-5. Epub 2020 Apr 01. PMID: 32239313.
Copy Download .nbib Format: NLM
A golden tube following bioresorbable scaffold implantation.

Kardiologia polska

Basavarajaiah S, Kalkat H, Watkin R.
PMID: 32395974
Kardiol Pol. 2020 Aug 25;78(7):782-783. doi: 10.33963/KP.15355. Epub 2020 May 11.

No abstract available.

Cite
Basavarajaiah S, Kalkat H, Watkin R. A golden tube following bioresorbable scaffold implantation. Kardiol Pol. 2020;78(7):782-783doi: 10.33963/KP.15355.
Basavarajaiah, S., Kalkat, H., & Watkin, R. (2020). A golden tube following bioresorbable scaffold implantation. Kardiologia polska, 78(7), 782-783. https://doi.org/10.33963/KP.15355
Basavarajaiah, Sandeep, et al. "A golden tube following bioresorbable scaffold implantation." Kardiologia polska vol. 78,7 (2020): 782-783. doi: https://doi.org/10.33963/KP.15355
Basavarajaiah S, Kalkat H, Watkin R. A golden tube following bioresorbable scaffold implantation. Kardiol Pol. 2020 Aug 25;78(7):782-783. doi: 10.33963/KP.15355. Epub 2020 May 11. PMID: 32395974.
Copy Download .nbib Format: NLM
Harnessing Real-World Evidence for the Development of Novel Cancer Therapies.

Trends in cancer

Greshock J, Lewi M, Hartog B, Tendler C.
PMID: 32972882
Trends Cancer. 2020 Nov;6(11):907-909. doi: 10.1016/j.trecan.2020.08.006. Epub 2020 Sep 21.

Resourcing real-world evidence (RWE) is becoming an increasingly important asset in developing novel therapies for cancer. In this article, an overview of the benefits and challenges of using these data is provided. Through several case examples we highlight future...

Cite
Greshock J, Lewi M, Hartog B, et al. Harnessing Real-World Evidence for the Development of Novel Cancer Therapies. Trends Cancer. 2020;6(11):907-909doi: 10.1016/j.trecan.2020.08.006.
Greshock, J., Lewi, M., Hartog, B., & Tendler, C. (2020). Harnessing Real-World Evidence for the Development of Novel Cancer Therapies. Trends in cancer, 6(11), 907-909. https://doi.org/10.1016/j.trecan.2020.08.006
Greshock, Joel, et al. "Harnessing Real-World Evidence for the Development of Novel Cancer Therapies." Trends in cancer vol. 6,11 (2020): 907-909. doi: https://doi.org/10.1016/j.trecan.2020.08.006
Greshock J, Lewi M, Hartog B, Tendler C. Harnessing Real-World Evidence for the Development of Novel Cancer Therapies. Trends Cancer. 2020 Nov;6(11):907-909. doi: 10.1016/j.trecan.2020.08.006. Epub 2020 Sep 21. PMID: 32972882.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 224 entries